Related Experiment Videos
[A randomized prospective study on combined chemoradiotherapy for non-small cell lung cancer]
1Department of Radiation Oncology,Third Clinical Hospital,Harbin Medical University,Harbin,Heilongjiang 150040,P.R.China.
Background:
To observe and compare the effect of radiation alone and combined chemoradiation for non-small cell lung cancer.
Methods:
From January,1995 to December,1997,82 eligible patients with non-small cell lung cancer were randomized into two groups and 74 of them could be evaluated: radiation group (35 cases) and combined group (39 cases).In the combined group,21 cases received sensibilization chemotherapy (fluoracil and cisplatin were administered in the first and fourth week of radiation) and 18 cases received combined chemotherapy regimen (carboplatin and cisplatin,etoposide,ifosphamide,cyclophosphamide and so on,were administered before,during or after radiation for at least two courses).
Results:
The complete response was 23% (8/35) in the radiation group and 41% (16/39) in the combined group.The 1-,2- and 3-year survival rates in the radiation group and combined group were 48% and 65%,27% and 38%,18% and 19% respectively (P>0.05);the median survival time was 11 months and 18.9 months respectively.For stage III patients,the 1-,2- and 3-year survival rates were 42% and 67%,25% and 38%,13% and 21% respectively in the radiation group and combined group (P<0.05),and 58% and 72%,38% and 36%,26% and 12% respectively in the sensibilization chemotherapy group and combined chemotherapy regimen group (P>0.05).
Conclusions:
Combined chemoradiation therapy can strikingly increase the 1-,2- and 3-year survival rate for stage III patients with non-small cell lung cancer,and the survival rate for sensibilization chemotherapy and combined chmotherapy regimen needs more observation on enough cases.
